NMTC (NeuroOne Medical Technologies Corporation Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by NMTC officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-08 | David J. Wambeke | Chief Business Officer | Buy | — | — |
| 2026-08-28 | David A Rosa | CEO & President | A | — | — |
| 2026-08-28 | Christopher Volker | Chief Financial Officer | A | — | — |
| 2026-08-28 | Emily J. Johns | Chief Administrative Officer | A | — | — |
| 2026-08-28 | Mark Christianson | Market Development Director | A | — | — |
| 2026-08-28 | Steve Mertens | Chief Technology Officer | A | — | — |
| 2026-07-02 | Mark Christianson | Market Development Director | Sell | — | — |
| 2026-04-07 | JEFFREY S MATHIESEN | Director | A | — | — |
| 2026-04-07 | Edward Andrle | Director | A | — | — |
| 2026-04-07 | Jason Richard Mills | Director | A | — | — |
| 2026-04-07 | PAUL BUCKMAN | Director | A | — | — |
| 2026-04-01 | David A Rosa | CEO and President | F | — | — |
| 2026-04-01 | Mark Christianson | Business Development Director | MIXED | — | — |
| 2026-04-01 | Steve Mertens | Chief Technology Officer | F | — | — |
| 2026-03-16 | Mark Christianson | Business Development Director | Sell | — | — |
| 2026-03-12 | Mark Christianson | Business Development Director | Sell | — | — |
| 2026-03-03 | David J. Wambeke | Chief Business Officer | Buy | — | — |
| 2026-02-20 | Mark Christianson | Business Development Director | F | — | — |
| 2026-02-20 | David A Rosa | CEO and President | F | — | — |
| 2026-02-20 | Steve Mertens | Chief Technology Officer | F | — | — |
| 2026-01-05 | Mark Christianson | Business Development Director | F | — | — |
| 2026-01-05 | Steve Mertens | Chief Technology Officer | F | — | — |
| 2026-01-05 | David A Rosa | CEO and President | F | — | — |
| 2026-01-02 | Jason Richard Mills | Director | A | — | — |
| 2025-10-01 | David A Rosa | CEO and President | F | — | — |
| 2025-10-01 | Mark Christianson | Business Development Director | F | — | — |
| 2025-10-01 | Steve Mertens | Chief Technology Officer | F | — | — |
| 2025-09-09 | Mark Christianson | Business Development Director | Sell | — | — |
| 2025-07-02 | David A Rosa | CEO and President | F | — | — |
| 2025-07-02 | Steve Mertens | Chief Technology Officer | F | — | — |
| 2025-07-02 | Mark Christianson | Business Development Director | F | — | — |
| 2025-06-25 | JEFFREY S MATHIESEN | Director | A | — | — |
| 2025-06-25 | PAUL BUCKMAN | Director | A | — | — |
| 2025-06-25 | Edward Andrle | Director | A | — | — |
| 2025-06-05 | Mark Christianson | Business Development Director | Sell | — | — |
| 2025-06-03 | Emily J. Johns | General Counsel | A | — | — |
| 2025-05-23 | Mark Christianson | Business Development Director | Sell | — | — |
| 2025-05-21 | Mark Christianson | Business Development Director | Sell | — | — |
| 2025-04-21 | Steve Mertens | Chief Technology Officer | A | — | — |
| 2025-04-21 | David A Rosa | CEO and President | A | — | — |
| 2025-04-21 | Ronald W. McClurg | Chief Financial Officer | A | — | — |
| 2025-04-21 | Christopher Volker | Chief Operating Officer | A | — | — |
| 2025-04-21 | Mark Christianson | Business Development Director | A | — | — |
| 2025-04-07 | Ronald W. McClurg | Chief Financial Officer | Buy | — | — |
| 2025-04-07 | David A Rosa | CEO and President | Buy | — | — |
| 2025-04-02 | David A Rosa | CEO and President | F | — | — |
| 2025-04-02 | Mark Christianson | Business Development Director | F | — | — |
| 2025-04-02 | Steve Mertens | Chief Technology Officer | F | — | — |
| 2025-02-20 | David A Rosa | CEO and President | F | — | — |
| 2025-02-20 | Steve Mertens | Chief Technology Officer | F | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Chief Business Officer | 199,999 | — |
| — | CEO & President | 180,022 | — |
| — | Chief Financial Officer | 74,020 | — |
| — | Director | 29,789 | — |
| — | Director | 26,057 | — |
| — | Chief Technology Officer | 25,357 | — |
| — | Director | 22,322 | — |
| — | Market Development Director | 20,692 | — |
| — | Chief Financial Officer | 12,500 | — |
| — | Director | 8,281 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the NMTC quote page; the site-wide leaderboard is on the insider transactions hub.